Introduction
============

DNA methylation by addition of a methyl group to cytosines followed by guanines \[CpG sites\] (5-methylcytosine \[5mC\]), is a mechanism of gene regulation. Methylation of CpG rich regions inhibits binding of gene regulatory machinery, leading to transcription silencing. Consequently, gene dysregulation via aberrant DNA methylation is an important contributor to disease. Evidence suggests that DNA methylation has an important role in neurological disorders, such as cognitive impairments ([@B24]), and alterations of DNA methylation contribute to the onset of Alzheimer's disease (AD), since they were detected in autopsied brain DNA from 708 prospectively collected pre-symptomatic subjects ([@B11]); global levels of 5mC and 5-hydroxymethylcytosine (5hmC; the first oxidative product in the demethylation of 5mC) were positively correlated with markers of AD, including amyloid beta, tau, and ubiquitin loads, and levels of 5mC and 5hmC were low in astrocytes and microglia, while they were elevated in neurons ([@B10]). While genomic DNA molecules are generally resistant to change in response to noncarcinogenic environmental factors, DNA methylation is more plastic and can be altered relatively easily by a variety of subtle exposures. Hence, regulation of such epigenetic changes is potentially an effective strategy to delay the progression of AD pathology.

*Ganoderma lucidum* is a Basidiomycetes fungus (order, Polyporales) that is popular as a medicinal mushroom and has been used since ancient times as a folk remedy in Asia, due to its diverse health-promoting properties ([@B7]; [@B8]). *G. lucidum* is highly effective in decreasing cell senescence and has antioxidant properties ([@B12]; [@B6]). The beneficial properties of *G. lucidum* are associated with a broad variety of bioactive compounds present in the fruiting body, mycelium, and spores, including polysaccharides, triterpenes, ganoderiols, sterols, amino acids, and nucleotides ([@B30]). In our previous study, we investigated *G. lucidum* metabolites and isolated 35 lanostane-type triterpenoids ([@B4]), including ganoderiols A, B, D, E, F, and M, and various ganoderic acids (β, A, B, C, C2, D2, d, E, F, G, J, H, and AM, among others) ([@B31], [@B27]; [@B32]; [@B17]). APP/PS1 double transgenic mice express mutated human presenilin (DeltaE9) and human murine amyloid precursor protein (APPswe) fusions, both of which are present in familial AD patients. SAMP8 is a natural pathogenesis model associated with progressive aging, similar to AD. It is accompanied by the natural occurrence of dementia, brain atrophy, cortical and hippocampal neuronal shedding, and β-amyloid deposition. Both models are currently widely used for disease research in AD. In this study, to determine the pharmacologically active ingredients of *G. lucidum* and investigate their modes of action in AD and/or other age-related diseases, a rat model of aging rat was generated by intraperitoneal (i.p.) injection of 100 mg/kg/d [D]{.smallcaps}-galactose for 8 weeks ([@B35]; [@B18]) and used to screen for the anti-aging effects of the main active extracts from *G. lucidum*. The effects of these extracts on DNA methylation were also evaluated by whole genome bisulfite sequencing of samples from SAMP8 and APP/PS1 mouse models of AD.

Materials and Methods {#s1}
=====================

Preparation of *Ganoderma lucidum* Extracts
-------------------------------------------

The fresh fruit bodies of *G. lucidum* were collected from the Mushroom Garden of Guangdong Yuewei Edible Fungi Technology Co., Ltd. and were identified by YX. A voucher specimen (No. GL20160322) has been deposited in the Herbarium of Microbiology Institute of Guangdong. The *Ganoderma lucidum* dried at 70°C and then ground into fine powders that could passed through a sieve with 30 pores per square inch.

5,000 g of powders of the *Ganoderma lucidum* were extracted with petroleum ether (1:10, w/v) in an incubator at 70°C for 1 h. Collected the extracted liquid and repeated the operation above once again, then combined extracted liquid. After cooling down to normal temperature, the extracted liquid were filtered, the filtrate was concentrated to dryness under vacuum using a rotary evaporator, then the *G. lucidum* oil extracts (OEG) were got.

The filter residue were extracted with ethyl acetate in an incubator at 75°C for 2 h. Collected the extracted liquid and repeated the operation above once again, then combined extracted liquid. The filtrate was concentrated to dryness under vacuum using a rotary evaporator. Take part of the extract above to re-dissolve in methanol, and then added into a chromatographic column with absorbing material C18, use gradiently elution with water and methanol, collected the eluant of 40--75% aqueous methanol solution. Then the eluant was concentrated to dryness using a rotary evaporator under vacuum and then the extracts of *G. lucidum* small molecule compounds (AEG) were got, which stored at 4°C. The extracts of *G. lucidum* small molecule compounds (AEG) were analysis by HPLC-UV ([Figure 1](#F1){ref-type="fig"}), mostly containing triterpenic acids and triterpene alcohols ([@B4]), ganoderenic acid C (0.177 mg/g), ganoderenic acid C2 (0.39 mg/g), ganoderic acid G (0.81 mg/g), ganoderenic acid B (0.30 mg/g), ganoderic acid B (0.75 mg/g), ganoderic acid A (1.46 mg/g), ganoderic acid H (2.24 mg/g), ganoderenic acid D (0.28 mg/g), ganoderic acid D (1.14 mg/g), ganoderic acid F (2.13 mg/g), then stored at 4°C.

![HPLC-UV analysis the *G. lucidum* lipophilic components. **(A)** Ten chemical reference substance from *G. lucidum*. **(B)** The HPLC-fingerprint of *G. lucidum* lipophilic components.](fphar-10-00272-g001){#F1}

The last filter residue were extracted with water in an incubator at 100°C for 2.5 h. Collected the extracted liquid and repeated the operation above once again, then combined extracted liquid. The filtrate was concentrated under vacuum using a rotary evaporator. Then the polysaccharides were precipitated from the filtrate in 80% aqueous ethanol (V/V) at 4°C overnight. The polysaccharides were centrifuged at 5,000 r/min for 10 min and further lyophilized in a freeze dryer (Alphai-4LD plus, CHRZST). The *G. lucidum* polysaccharides extracts (PEG) were got.

Animal Model Generation and Treatment
-------------------------------------

Adult male Sprague-Dawley rats (180--220 g) obtained from the Center for Laboratory Animals, Guangdong Province (Certification No: SCXK \[Yue\] 2008-0020 and SYXK \[Yue\] 2008-0085), were pair-housed in plastic cages in a temperature-controlled room (25°C) with a 12/12-h light/dark cycle. Food and water were available *ad libitum*. All experimental protocols were approved by the Center for Laboratory Animals of the Guangdong Institute of Microbiology. All efforts were made to minimize the number of animals used.

For testing which main extracts of *G. lucidum* are active in anti-aging, a rat model of aging was generated by intraperitoneal (i.p.) injection of 100 mg/\[kg⋅d\] [D]{.smallcaps}-galactose for 8 weeks ([@B35]; [@B18]) and treated with polysaccharide (PEG), alcohol (AEG), and oil (OEG) extracts from *G. lucidum* by gavage. Male rats were randomly divided into seven groups treated as follows: (1) control group, oral distilled water only; (2) model group, [D]{.smallcaps}-galactose (100 mg/\[kg⋅d\]); (3) low-dose AEG group (AEGL), [D]{.smallcaps}-galactose (100 mg/\[kg⋅d\]) + AEG (50 mg/\[kg⋅d\]); (4) high-dose AEG group (AEGH), [D]{.smallcaps}-galactose (100 mg/\[kg⋅d\]) + AEG (100 mg/\[kg⋅d\]); (5) low-dose PEG group (PEGL), [D]{.smallcaps}-galactose (100 mg/\[kg⋅d\]) + PEG (50 mg/\[kg⋅d\]); (6) high-dose PEG group (PEGH), [D]{.smallcaps}-galactose 100 mg/\[kg⋅d\] + PEG (100 mg/\[kg⋅d\]); (7) OEG group, [D]{.smallcaps}-galactose (100 mg/\[kg⋅d\]) + 0.5 ml OEG. Female rats were randomly divided into four groups treated as follows: (1) control group, oral distilled water; (2) model group, [D]{.smallcaps}-galactose (100 mg/\[kg⋅d\]) only; (3) low-dose AEG group, [D]{.smallcaps}-galactose (100 mg/\[kg⋅d\]) + AEG (50 mg/\[kg⋅d\]); (4) high-dose AEG group, [D]{.smallcaps}-galactose (100 mg/\[kg⋅d\]) + AEG (100 mg/\[kg⋅d\]). Rats were treated every day in the morning. Each group consisted of eight animals and treatment continued for 8 weeks.

Thirty male APP/PS1, 30 male SAMP8 transgenic mice (2 months old), and 10 C57BL/6J male mice with the same age and same genetic background were purchased from the Beijing HFK Bioscience Co. Ltd. \[Certificate No: SCXK (Jing) 2014--0004\]. The mean body weight of the mice was 20 ± 5 g. All animal experiments began at least 4 weeks after the animals arrived at our facility. Mice were randomly allocated into three groups: (1) AD model; (2) low-dose group, oral AEG (50 mg/\[kg⋅d\]); (3) high-dose group, intragastrically AEG (100 mg/\[kg⋅d\]) (*n* = 8 per group). The 10 C57BL/6J mice were used as the control group. The control and AD model groups were treated with volumes of distilled water equal to those of extracts (dissolved in distilled water) of *G. lucidum* used to treat mice. Treatments were administered intragastrically once daily for 24 weeks.

Measurement of AD Parameters
----------------------------

The spatial learning and memory abilities of rats and mice were tested using a Morris water maze (MWM, DMS-2, Chinese Academy of Medical Sciences, Institute of Medicine). MWM tests included three periods, (1) initial spatial training, (2) spatial reversal training, and (3) the probe test, and were conducted as described previously ([@B3]). Animal weights were measured every 3 days during the drug administration period. Following water maze testing, blood and serum were acquired. Routine indices and cytokines ([@B29]) were measured and the brains of the animals dissected. Four brains from each group were fixed in 4% paraformaldehyde solution and prepared as paraffin sections.

Sections were stained with hematoxylin--eosin (HE) or by immunohistochemistry and observed by light microscopy ([@B33]; [@B3]). Immunostaining for Aβ~1-42~, Histone H3, DNMT3A, and DNMT3B was performed using paraffin-embedded 4 μm sections with the two-step peroxidase conjugated polymer technique (DAKO Envision kit, DAKO, Carpinteria, CA, United States), and primary antibodies against Aβ~1-42~ (1:1000), Histone H3 (1:500), DNMT3A (1:1000), and DNMT3B (1:500).

WGBS Library Preparation, Sequencing, Quality Analysis, and Mapping
-------------------------------------------------------------------

Triplicate brain tissues samples were collected for each group and genomic DNA extracted using a Qiagen AllPrep Mini Kit, according to the manufacturer's instructions. Isolated DNA samples were eluted in TE buffer, validated for quality and quantity using UV spectrophotometry, and stored long term at -80°C. DNA samples with an OD260/280 ratio between 1.75 and 1.85 were deemed high quality. Genomic DNA samples were sheared to 200--300 bp fragments using a Bioruptor Pico (Diagenode), with nine cycles of 30 s on and 30 s off. Suitable length DNA insertion fragments were prepared by interrupting 5 μg genomic DNA using high pressure nitrogen. DNA fragments with protruding terminals were repaired using 3′--5′ exonuclease and polymerase from the TruSeq Nano DNA LT Sample Prep Kit (Illumina). Next, an 'A' base was added to the 3′ end of repaired blunt DNA fragments, which were ligated to the labeled methylation adaptors. Conjugates were purified from agarose gels, and free and self-ligated molecules removed. Suitable DNA fragments were selected and treated with Bisulfite to convert unmethylated 'C' bases into 'U' bases. PCR was used to selectively enrich DNA fragments with adaptor molecules ligated to both ends, and the DNA library amplified. Products were quantified using the Agilent high sensitivity DNA assay on a Bioanalyzer 2100 system (Agilent). Libraries were then sequenced on the Hiseq platform (Illumina) by Shanghai Personal Biotechnology Corp. Ltd.

Transcriptome Analysis
----------------------

Total RNA was isolated using Trizol Reagent (Invitrogen Life Technologies) and the concentration, quality, and integrity determined using a NanoDrop spectrophotometer (Thermo Scientific). Three micrograms of RNA were used as input material for generation of sequencing libraries using the TruSeq RNA Sample Preparation Kit (Illumina, San Diego, CA, United States). Briefly, mRNA was purified from total RNA using poly-T oligo-attached magnetic beads. Fragmentation was carried out using divalent cations under elevated temperature in Illumina proprietary fragmentation buffer. First strand cDNA was synthesized using random oligonucleotides and SuperScript II. Subsequently, second strand cDNA synthesis was performed using DNA Polymerase I and samples treated with RNase H. Remaining overhangs were converted into blunt ends using exonuclease/polymerase enzymes, which were then removed. After adenylation of the 3′ ends of the DNA fragments, Illumina PE adapter oligonucleotides were ligated to prepare for hybridization. To select cDNA fragments of the preferred length (200 bp), libraries were purified using the AMPure XP system (Beckman Coulter, Beverly, CA, United States). DNA fragments with ligated adaptor molecules on both ends were selectively enriched using the Illumina PCR Primer Cocktail in a 15 cycle PCR reaction. Products were purified (AMPure XP system) and quantified using the Agilent high sensitivity DNA assay on a Bioanalyzer 2100 system (Agilent). Libraries were then sequenced on a Hiseq platform (Illumina) by Shanghai Personal Biotechnology Corp. Ltd.

Differentially expressed genes (DEGs) between treatment groups were identified by *de novo* assembly and annotation; expression levels of each transcript were measured according to the fragments/kb of exon per million mapped reads method. RSEM^[1](#fn01){ref-type="fn"}^ was used to quantify the abundance of genes and isoforms. The R statistical package software, EdgeR^[2](#fn02){ref-type="fn"}^, was used for analysis of differential expression. Functional enrichment analysis was performed to identify DEGs significantly enriched in Gene Ontology (GO) and metabolic pathways, using a Bonferroni-corrected *p*-value cut-off of ≤0.05, compared with the whole-transcriptome background. GO functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed using Goatools^[3](#fn03){ref-type="fn"}^ and KOBAS^[4](#fn04){ref-type="fn"}^, respectively ([@B31]; [@B2]; [@B25]).

Bisulfite Sequencing PCR (BSP)
------------------------------

In this study, two regions with relatively high levels of methylation in SAMP8, APP/PS1, and Control mice, were randomly chosen to validate the results of WGBS. Primers used to amplify *AKT2* (Chromosome 1: 84411726--84450162+) and *MAPK3* (Chromosome 1: 15412603--15613746+) are illustrated in [Figure 5](#F5){ref-type="fig"}. Bisulfite conversion of genomic DNA was performed using an EpiTect^®^ Plus DNA Bisulfite Kit (59124, Qiagen). The PCR program was as follows: initial denaturation at 94°C for 5 min; 30 cycles of 94°C for 30 s, 56°C annealing for 30 s, and 72°C for 30 s; and a final extension at 72°C for 5 min. PCR products were separated and detected on 1% agarose gel, purified using a QIA quick Gel Extraction Kit (28704, Qiagen), cloned into linearized vector using T~4~ DNA Ligase, and transformed into *Trans*-T1 cells. Ten subclones were selected for each fragment and subsequently sequenced using the ABI 3730XL sequencing platform.

Statistical Analysis
--------------------

All data are described as the means ± standard deviations (SD) of at least three independent experiments. The significance of differences between treatments were analyzed by one-way analysis of variance (ANOVA) tests, with *p* \< 0.05 considered significant, using statistical package for the social sciences (SPSS, Abacus Concepts, Berkeley, CA, United States) and Prism5 (GraphPad, San Diego, CA, United States) software.

Results
=======

Screening the Main *G. lucidum* Active Extracts for Anti-aging Properties
-------------------------------------------------------------------------

The fur of animals treated with *G. lucidum* extracts was much smoother than that of those in the model group. The average weight of animals did not differ significantly between the treated and model groups (*p* \> 0.05); male animals weighed approximately 320 g at the beginning and 500 g at the end of the experiment ([Figure 2A](#F2){ref-type="fig"}), while female rats weighed approximately 240 g at the beginning and 290 g at the end of the experiment ([Figure 2B](#F2){ref-type="fig"}).

![Screening the main active extracts from *Ganoderma lucidum* extracts on anti-aging in the [D]{.smallcaps}-galactose induced deficient rats. The male rats were randomly divided into seven groups as follows: (1) control group, oral distilled water only; (2) model group, [D]{.smallcaps}-galactose (100 mg/\[kg⋅d\]); (3) low-dose AEG group (AEGL), [D]{.smallcaps}-galactose (100 mg/\[kg⋅d\]) + AEG (50 mg/\[kg⋅d\]); (4) high-dose AEG group (AEGH), [D]{.smallcaps}-galactose (100 mg/\[kg⋅d\]) + AEG (100 mg/\[kg⋅d\]); (5) low-dose PEG group (PEGL), [D]{.smallcaps}-galactose (100 mg/\[kg⋅d\]) + PEG (50 mg/\[kg⋅d\]); (6) high-dose PEG group (PEGH), [D]{.smallcaps}-galactose 100 mg/\[kg⋅d\] + PEG (100 mg/\[kg⋅d\]); (7) OEG group, [D]{.smallcaps}-galactose (100 mg/\[kg⋅d\]) + 0.5 ml OEG. Female rats were randomly divided into four groups treated as follows: (1) control group, oral distilled water; (2) model group, [D]{.smallcaps}-galactose (100 mg/\[kg⋅d\]) only; (3) low-dose AEG group, [D]{.smallcaps}-galactose (100 mg/\[kg⋅d\]) + AEG (50 mg/\[kg⋅d\]); (4) high-dose AEG group, [D]{.smallcaps}-galactose (100 mg/\[kg⋅d\]) + AEG (100 mg/\[kg⋅d\]), polysaccharide (PEG), alcohol (AEG), and oil (OEG) extracts from *G. lucidum* by gavage. Every group consisted of eight animals and the procedure duration was 8 weeks. **(A)** Male animals weighed; **(B)** While female rats weighed; **(C,D)** Morris water maze tests; **(E)** Brain tissue HE staining. ^∗∗^*p* \< 0.01.](fphar-10-00272-g002){#F2}

In MWM tests, compared to the model group (100.11 ± 9.37 s), the incubation periods for each of the groups treated with *G. lucidum* extracts treated were longer or shorter. On the first day, the incubation period for the low-dose AEG group was 86.37 ± 11.46 s and that for the high-dose group was 82.00 ± 19.44 s, which were significantly shorter than the model group (*p* \< 0.01). On the fourth day, the incubation period for the low-dose AEG group was 39.30 ± 5.63 s and that for the high-dose group was 30.74 ± 3.69 s, and the differences were significant relative to the model group (*p* \< 0.01; [Figure 2C](#F2){ref-type="fig"}), demonstrating that administration of AEG could ameliorate [D]{.smallcaps}-galactose-induced learning and memory dysfunction in rats and that the main active anti-aging extract from *G. lucidum* resides in the alcohol extracts.

The swimming time of the control group in the NW quadrant (47.20 ± 1.82 s) was significantly longer than that in the other three quadrants (*p* \< 0.01). The swimming time in the NW quadrant of the model group was 25.23 ± 2.66 s, which was significantly shorter than that of the control group (*p* \< 0.01), suggesting that the rats remembered the location of the placement of the platform. The swimming durations of the low- and high-dose AEG groups were 57.55 ± 1.39 s and 49.16 ± 1.87 s, respectively, which were significantly longer than the model group. Compared with the model group, the differences were significant (*p* \< 0.01; [Figure 2D](#F2){ref-type="fig"}). The other extracts treated groups do not improved so much ([Figure 2](#F2){ref-type="fig"}).

In the control group, pyramidal cells in the CA1 region were arranged precisely and tightly, and no cell loss was observed. Additionally, in the control group, the cells were round and intact with clearly stained, dark blue nuclei ([Figure 2E](#F2){ref-type="fig"}). In contrast, in the model groups, noticeable damage in the hippocampus was observed by histopathology. The layered pyramidal structure was disrupted, and neuronal loss was observed in the CA1 region, and there were neurons with pyknotic nuclei and shrunken or irregular shape. These abnormalities were reduced by treatment with AEG. There were greater numbers of cells with superior cell morphology in the AEG-treated group compared with the untreated groups; with a greater difference in the AEGH group compared with the AEGL group. Together, these results demonstrate that the main active anti-aging extract from *G. lucidum* resides in the alcohol extracts.

WGBS of AEG-Treated [D]{.smallcaps}-Galactose-Induced Deficient Rats
--------------------------------------------------------------------

Three whole brains dissected from each of the [D]{.smallcaps}-galactose-induced model, AEG-treated, and control rats were pooled to provide one sample per group and analyzed by WGBS. As shown in [Table 1](#T1){ref-type="table"}, there were fewer methylated CpG sites in the model group (74.9%) than in controls (77.5%), whereas the AEG-treated group recovered to a value of 76.5%, indicating that excessive [D]{.smallcaps}-galactose inhibits DNA methylation changes in the brain and that alcohol extracts from *G. lucidum* can ameliorate this dysregulation (*p* \< 0.05). Details of the methylated strands and the distributions of methylated genes are presented in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, respectively. A whole genome methylation circular map generated using Circos ([@B16]) is provided in [Figure 3A](#F3){ref-type="fig"}.

###### 

Cytosine context methylation analysis of brain tissues in AEG-treated [D]{.smallcaps}-galactose-induced deficient rats.

  Sample    Total cytosine   Type             CpG           CHG             CHH              Unknown context
  --------- ---------------- ---------------- ------------- --------------- ---------------- -----------------
  AEG       15,534,176,963   Methylated C     595,389,651   149,008,458     479,858,609      7,652
                             Unmethylated C   183,141,321   3,462,346,734   10,664,432,190   115,883
                             percentage       76.5%         4.1%            4.3%             6.2%
  Model     17,010,810,890   Methylated C     641,046,353   164,343,883     535,114,480      9,011
                             Unmethylated C   214,607,050   3,724,896,568   11,730,802,556   130,840
                             percentage       74.9%         4.2%            4.4%             6.4%
  Control   14,965,478,059   Methylated C     598,105,218   151,106,866     475,851,826      7,641
                             Unmethylated C   174,027,353   3,400,594,438   10,165,792,358   108,386
                             percentage       77.5%         4.3%            4.5%             6.6%

Alcohol (AEG) extracts from
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by gavage

.

###### 

Methylated strand analysis of brain tissues in AEG-treated [D]{.smallcaps}-galactose-induced deficient rats.

  Sample    Type       Counts        Description
  --------- ---------- ------------- ------------------------------------------------
  AEG       CT/GA/CT   133,585,197   \[(Converted) top strand\]
            GA/CT/CT   0             \[Complementary to (converted) top strand\]
            GA/CT/GA   0             \[Complementary to (converted) bottom strand\]
            CT/GA/GA   131,851,325   \[(Converted) bottom strand\]
  Model     CT/GA/CT   144,205,567   \[(Converted) top strand\]
            GA/CT/CT   0             \[Complementary to (converted) top strand\]
            GA/CT/GA   0             \[Complementary to (converted) bottom strand\]
            CT/GA/GA   142,325,935   \[(Converted) bottom strand\]
  Control   CT/GA/CT   126,675,501   \[(Converted) top strand\]
            GA/CT/CT   0             \[Complementary to (converted) top strand\]
            GA/CT/GA   0             \[Complementary to (converted) bottom strand\]
            CT/GA/GA   124,160,178   \[(Converted) bottom strand\]
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###### 

The distribution of methylated genes analysis of brain tissues in AEG-treated [D]{.smallcaps}-galactose-induced deficient rats.

  Sample    Group           Total_bases   Tag_count     Tags/Kb
  --------- --------------- ------------- ------------- ---------
  Control   CDS_Exons       39,977,515    8,921,362     223.16
            5'UTR_Exons     3,002,257     602,843       200.8
            3'UTR_Exons     13,709,583    2,927,376     213.53
            Introns         817,405,745   163,673,356   200.24
            TSS_up_1kb      27,119,038    3,934,857     145.1
            TSS_up_5kb      123,811,475   18,469,306    149.17
            TSS_up_10kb     226,283,650   33,787,938    149.32
            TES_down_1kb    27,042,568    4,078,199     150.81
            TES_down_5kb    118,479,240   17,748,831    149.81
            TES_down_10kb   212,554,470   31,527,752    148.33
  AEG       CDS_Exons       39,977,515    11,261,049    281.68
            5'UTR_Exons     3,002,257     562,354       187.31
            3'UTR_Exons     13,709,583    2,853,633     208.15
            Introns         817,405,745   167,349,858   204.73
            TSS_up_1kb      27,119,038    4,018,422     148.18
            TSS_up_5kb      123,811,475   19,016,199    153.59
            TSS_up_10kb     226,283,650   34,838,221    153.96
            TES_down_1kb    27,042,568    4,120,303     152.36
            TES_down_5kb    118,479,240   18,083,259    152.63
            TES_down_10kb   212,554,470   32,215,190    151.56
  Model     CDS_Exons       39,977,515    12,861,620    321.72
            5'UTR_Exons     3,002,257     710,562       236.68
            3'UTR_Exons     13,709,583    3,171,679     231.35
            Introns         817,405,745   182,489,824   223.25
            TSS_up_1kb      27,119,038    4,522,338     166.76
            TSS_up_5kb      123,811,475   20,747,720    167.58
            TSS_up_10kb     226,283,650   37,789,603    167
            TES_down_1kb    27,042,568    4,517,278     167.04
            TES_down_5kb    118,479,240   19,633,194    165.71
            TES_down_10kb   212,554,470   34,863,583    164.02

Alcohol (AEG) extracts from

G. lucidum

by gavage

.

![**(A)** The whole genome methylation circular map of [D]{.smallcaps}-galactose induced deficient rats. From the outside to the inner: the first circle is genome; the second circle is the distribution of genome, the red circle is positive chain gene and the green is negative chain gene; the third circle is the distribution of genomic GC content; the fourth is the sequencing depth of all samples; the fifth circle is the control group, the sixth is the AEG-treated group, and the seventh is the model group. Control group that received oral distilled water, model group that received intraperitoneal injection (i.p.) of 100 mg/\[kg⋅d\] [D]{.smallcaps}-galactose, AEG-treated group that received [D]{.smallcaps}-galactose (100 mg/\[kg⋅d\]) + AEG (100 mg/\[kg⋅d\]). **(B)** The whole genome methylation circular map of APP/PS1 and SAMP8 mice. From the outside to the inner: the first circle is genome of mice; the second circle is the distribution of genome, the red circle is positive chain gene and the green is negative chain gene; the third circle is the distribution of genomic GC content; the fourth is the SAMP8 model group, the fifth is AEG-treated group on SAMP8 mice, the sixth is the AEG-treated group on APP/PS1 mice, and the seventh is the APP/PS1 model group, the eighth is the control group. Control and model group that received oral distilled water; AEG-treated group at a dosage of 100 mg/\[kg⋅d\] in AEG, and the extracts were dissolved in distilled water and were given by intragastric administration once daily for 24 weeks, polysaccharide (PEG), alcohol (AEG), and oil (OEG) extracts from *G. lucidum* by gavage.](fphar-10-00272-g003){#F3}

Bioinformatic analysis of GO and KEGG enrichment for genes with methylation affected by extracts of *G. lucidum* demonstrated that it can influence the estrogen signaling pathway, steroid hormone biosynthesis, long-term depression, renin secretion, the cGMP-PKG signaling pathway, glutamatergic synapses, B cell receptor signaling, serotonergic synapses, prolactin signaling, insulin secretion, gap junctions, GnRH signaling, phospholipase D signaling, cholinergic synapses, TNF signaling, retinol metabolism, long-term potentiation, purine metabolism, thyroid hormone synthesis, and sphingolipid signaling. Additional details are shown in [Supplementary Tables S1--S3](#SM1){ref-type="supplementary-material"}. These WGBS results demonstrate that alcohol extracts from *G. lucidum* can regulate DNA methylation in the brains of [D]{.smallcaps}-galactose-induced deficient rats.

Effects of AEG on DNA Methylation inAPP/PS1 and SAMP8 Mice
----------------------------------------------------------

To further understand the mechanism of action of AEG on DNA methylation, the whole brains dissected from SAMP8, AEG-treated SAMP8, APP/PS1, AEG-treated APP/PS1 and control mice, three per group, were pooled to generate one sample per group, and analyzed by WGBS. As shown in [Table 4](#T4){ref-type="table"}, the percentage of methylated CpG sites in the SAMP8 group was 73.7% and that in APP/PS1 mice was 76.0%, which were both lower than the control value (77.5%), while the AEG-treated groups showed recovery to 74.7 and 77.1%, indicating that alcohol extracts from *G. lucidum* can ameliorate dysregulation of methylation, particularly in APP/PS1 mice, where the effects were significant (*p* \< 0.05). Details of the methylated strands and the distributions of methylated genes are presented in [Tables 5](#T5){ref-type="table"}, [6](#T6){ref-type="table"}, respectively. A circular whole genome methylation map generated using Circos is presented in [Figure 3B](#F3){ref-type="fig"}.

###### 

Cytosine context methylation of AEG on DNA methylation in APP/PS1 and SAMP8 mice.

  Sample        Total cytosine   Type             CpG           CHG             CHH              Unknown context
  ------------- ---------------- ---------------- ------------- --------------- ---------------- -----------------
  SAMP8         12,072,778,86    Methylated C     281,115,405   100,751,628     330,787,246      20
                                 Unmethylated C   100,512,967   1,906,796,619   6,245,659,817    364
                                 Percentage       73.7%         5.0%            5.0%             5.2%
  AEG-SAMP8     15,534,176,963   Methylated C     271,926,316   96,803,506      318,028,942      18
                                 Unmethylated C   91,944,767    1,845,639,001   6,064,557,392    345
                                 Percentage       74.7%         5.0%            5.0%             5.0%
  AEG-APP/PS1   17,010,810,890   Methylated C     287,541,533   95,762,475      314,480,144      19
                                 Unmethylated C   85,633,466    1,875,234,074   6,152,398,180    374
                                 Percentage       77.1%         4.9%            4.9%             4.8%
  APP/PS1       12,072,778,866   Methylated C     308,957,749   101,474,938     330,703,258      27
                                 Unmethylated C   97,761,611    2,004,916,312   6,502,006,323    395
                                 Percentage       76.0%         4.8%            4.8%             6.4%
  Control       14,965,478,059   Methylated C     598,105,218   151,106,866     475,851,826      7,641
                                 Unmethylated C   174,027,353   3,400,594,438   10,165,792,358   108,386
                                 Percentage       77.5%         4.3%            4.5%             6.6%

Alcohol (AEG) extracts from

G. lucidum

by gavage

.

###### 

Methylated strand of AEG on DNA methylation in APP/PS1 and SAMP8 mice.

  Sample        Type       Counts        Description
  ------------- ---------- ------------- ------------------------------------------------
  SAMP8         CT/GA/CT   77,675,742    \[(Converted) top strand\]
                GA/CT/CT   0             \[Complementary to (converted) top strand\]
                GA/CT/GA   0             \[Complementary to (converted) bottom strand\]
                CT/GA/GA   75,938,750    \[(Converted) bottom strand\]
  AEG-SAMP8     CT/GA/CT   75,970,545    \[(Converted) top strand\]
                GA/CT/CT   0             \[Complementary to (converted) top strand\]
                GA/CT/GA   0             \[Complementary to (converted) bottom strand\]
                CT/GA/GA   74,617,468    \[(Converted) bottom strand\]
  AEG-APP/PS1   CT/GA/CT   77,022,081    \[(Converted) top strand\]
                GA/CT/CT   0             \[Complementary to (converted) top strand\]
                GA/CT/GA   0             \[Complementary to (converted) bottom strand\]
                CT/GA/GA   75,298,340    \[(Converted) bottom strand\]
  APP/PS1       CT/GA/CT   81,608,876    \[(Converted) top strand\]
                GA/CT/CT   0             \[Complementary to (converted) top strand\]
                GA/CT/GA   0             \[Complementary to (converted) bottom strand\]
                CT/GA/GA   79,632,061    \[(Converted) bottom strand\]
  Control       CT/GA/CT   126,675,501   \[(Converted) top strand\]
                GA/CT/CT   0             \[Complementary to (converted) top strand\]
                GA/CT/GA   0             \[Complementary to (converted) bottom strand\]
                CT/GA/GA   124,160,178   \[(Converted) bottom strand\]

Alcohol (AEG) extracts from
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###### 

The distribution of methylated genes of AEG on DNA methylation in APP/PS1 and SAMP8 mice.

  Sample        Group           Total_bases     Tag_count     Tags/Kb
  ------------- --------------- --------------- ------------- ---------
  SAMP8         CDS_Exons       92,770,739      10,520,478    113
                5'UTR_Exons     6,817,714       675,919       99
                3'UTR_Exons     30,830,041      3,147,020     102
                Introns         1,469,823,225   154,457,401   105
                TSS_up_1kb      29,802,851      1,894,436     64
                TSS_up_5kb      133,470,634     8,597,890     64
                TSS_up_10kb     239,135,684     15,695,506    66
                TES_down_1kb    31,715,036      1,963,976     62
                TES_down_5kb    137,780,250     8,829,933     64
                TES_down_10kb   242,815,081     16,089,066    66
  AEG-SAMP8     CDS_Exons       92,770,739      10,262,220    110.62
                5'UTR_Exons     6,817,714       662,568       97.18
                3'UTR_Exons     30,830,041      3,082,650     99.99
                Introns         1,469,823,225   150,628,394   102.48
                TSS_up_1kb      29,802,851      1,858,553     62.36
                TSS_up_5kb      133,470,634     8,429,922     63.16
                TSS_up_10kb     239,135,684     15,383,988    64.33
                TES_down_1kb    31,715,036      1,929,853     60.85
                TES_down_5kb    137,780,250     8,680,528     63
                TES_down_10kb   242,815,081     15,790,406    65.03
  AEG-APP/PS1   CDS_Exons       92,770,739      9,966,285     107.43
                5'UTR_Exons     6,817,714       650,467       95.41
                3'UTR_Exons     30,830,041      3,040,614     98.63
                Introns         1,469,823,225   149,238,024   101.53
                TSS_up_1kb      29,802,851      1,829,107     61.37
                TSS_up_5kb      133,470,634     8,285,235     62.08
                TSS_up_10kb     239,135,684     15,097,669    63.13
                TES_down_1kb    31,715,036      1,896,834     59.81
                TES_down_5kb    137,780,250     8,520,685     61.84
                TES_down_10kb   242,815,081     15,519,964    63.92
  APP/PS1       CDS_Exons       92,770,739      11,036,360    118.96
                5'UTR_Exons     6,817,714       687,146       100.79
                3'UTR_Exons     30,830,041      3,215,666     104.3
                Introns         1,469,823,225   158,021,162   107.51
                TSS_up_1kb      29,802,851      1,926,517     64.64
                TSS_up_5kb      133,470,634     8,726,063     65.38
                TSS_up_10kb     239,135,684     15,913,380    66.55
                TES_down_1kb    31,715,036      2,005,028     63.22
                TES_down_5kb    137,780,250     8,981,573     65.19
                TES_down_10kb   242,815,081     16,369,504    67.42
  Control       CDS_Exons       92,770,739      9,678,453     104.33
                5'UTR_Exons     6,817,714       640,382       93.93
                3'UTR_Exons     30,830,041      2,988,843     96.95
                Introns         1,469,823,225   146,269,536   99.52
                TSS_up_1kb      29,802,851      1,798,551     60.35
                TSS_up_5kb      133,470,634     8,120,448     60.84
                TSS_up_10kb     239,135,684     14,814,071    61.95
                TES_down_1kb    31,715,036      1,863,605     58.76
                TES_down_5kb    137,780,250     8,358,614     60.67
                TES_down_10kb   242,815,081     15,226,423    62.71
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The results of bioinformatic analysis of GO and KEGG enrichment of genes with differential methylation in treated mice are shown in [Supplementary Tables S2--S4](#SM1){ref-type="supplementary-material"}. These data show that *G. lucidum* can influence the adipocytokine signaling pathway, adrenergic signaling in cardiomyocytes, aldosterone synthesis and secretion, circadian entrainment, dopaminergic synapses, glutamatergic synapses, the GnRH signaling pathway, pancreatic secretion, the phosphatidylinositol signaling system, serotonergic synapses, and the thyroid hormone signaling pathway. More details are presented in [Supplementary Tables S5](#SM1){ref-type="supplementary-material"}, [S6](#SM1){ref-type="supplementary-material"}. Overall, these results show that alcohol extracts from *G. lucidum* can regulate DNA methylation in the brains of APP/PS1 and SAMP8 AD model mice.

mRNA Sequencing and Analysis
----------------------------

In APP/PS1 mice, 14732 mRNAs were identified as expressed in the brain, among which 1924 exhibited differential expression between the control and model groups (fold-change \> 1.50, *p* \< 0.05, [Supplementary Table S4](#SM1){ref-type="supplementary-material"}). Of these 1,924 DEGs, 990 were up-regulated and 934 were down-regulated ([Figure 4A](#F4){ref-type="fig"} and [Supplementary Table S7](#SM1){ref-type="supplementary-material"}). Bioinformatic analysis of GO and KEGG enrichment indicated involvement in GPCR ligand binding, class A/1 (rhodopsin-like receptors), the neuronal system, peptide ligand-binding receptors, neuroactive ligand-receptor interaction, calcium signaling, Rap 1 signaling, and glutamatergic synapses ([Figure 4B,C](#F4){ref-type="fig"}).

![The mRNA analysis of APP/PS1 and SAMP8 mice brain tissues. **(A--C)** is for APP/PS1; **(D--F)** is for SAMP8. Control and model group that received oral distilled water, AEG-treated group at a dosage of 100 mg/\[kg⋅d\] in AEG, and the extracts were dissolved in distilled water and were given by intragastric administration once daily for 24 weeks, alcohol (AEG) extracts from *G. lucidum* by gavage.](fphar-10-00272-g004){#F4}

Similarly, 14723 mRNAs were identified in the brains of SAMP8 mice, among which 1966 were differentially expressed in controls vs. the model group (fold-change \> 1.50, *p* \< 0.05, [Supplementary Table S4](#SM1){ref-type="supplementary-material"}). Of these, 820 were up-regulated and 1146 down-regulated ([Figure 4D](#F4){ref-type="fig"}). The results of bioinformatic analysis of GO and KEGG enrichment are shown in [Figure 4E,F](#F4){ref-type="fig"} and indicate enrichment for GPCR ligand binding, hemostasis, the neuronal system, class A/1 (rhodopsin-like receptors), neuroactive ligand-receptor interaction, calcium signaling, transcriptional misregulation in cancer, and adrenergic signaling in cardiomyocytes.

Overall, these data indicate that the alcohol extracts from *G. lucidum* can influence AD progression via multiple targets and certainly warrant further study.

BSP Confirmation
----------------

We used BSP to detect the methylation of CpG at the *AKT2* and *MAPK3* loci and compared the results for *G. lucidum*-treated and control mice ([Figure 5](#F5){ref-type="fig"}). The methylation of *AKT2* island 1 was 1.11% in AEG-APP/PS1 mice, 3.33% in APP/PS1 mice, and 2.22% in controls (*p* \< 0.05, [Figure 5](#F5){ref-type="fig"}). *AKT2* island 2 was 2.31% in AEG-SAMP8, 4.31% in SAMP8, and 0.77% in control mice (*p* \< 0.05, [Figure 5](#F5){ref-type="fig"}). Moreover, methylation of *MAPK3* was 3.20% in AEG-APP/PS1, 0.80% in AEG-SAMP8, 0.80% in APP/PS1, 1.26% in SAMP8, and 2.00% in control mice. Taken together, these data indicate a high level of consistency between the BSP and WGBS analyses and demonstrate that alcohol extracts of *G. lucidum* can regulate DNA methylation.

![Bisulfite sequencing PCR results of AKT2 (Chromosome 1: 84411726-84450162+) and MAPK3 (Chromosome 1: 15412603-15613746+) in APP/PS1 and SAMP8 mice brain tissues. Control and model group that received oral distilled water, AEG-treated group at a dosage of 100 mg/\[kg⋅d\] in AEG, and the extracts were dissolved in distilled water and were given by intragastric administration once daily for 24 weeks, alcohol (AEG) extracts from *G. lucidum* by gavage.](fphar-10-00272-g005){#F5}

Validation of the Negative Regulation of DNA Methyltransferases
---------------------------------------------------------------

Ingenuity Canonical Pathways and Networks analysis of mRNA results for AEG-APP/PS1, APP/PS1, and control group mice showed that molecules in the dataset targeted by the upstream regulator *Akt* included *BCL2A1*, *BMF*, *BTG2*, *CD44*, *CDH1*, *COL3A1*, *FOS*, *KCNA5*, *LCN2*, *MCAM*, *MMP9*, *PPP1R1B*, *RAG1*, and *RASD1*; a MAPK12-targeted molecule in the dataset was *MMP9*; HOXB3 targeted molecules in dataset included *HOXB4*, *HOXB5*, *HOXB6*, *HOXB7*, and *HOXB8* ([Figure 6](#F6){ref-type="fig"}); DNMT3A-targeted molecules were *CDH1*, *CNR1*, *EMX1*, *IRF5*, *KCNA1*, and *MYT1* ([Figure 6](#F6){ref-type="fig"}); DNMT3B-targeted molecules were *CDH1*, *CNR1*, *EMILIN2*, *FBXL16*, *GLT8D2*, *IRF5*, *KCNA1*, *KDELR3*, *MYT1*, *PRKCB*, *PRUNE2*, and *RPP25* ([Figure 6](#F6){ref-type="fig"}); and P38 MAPK-targeted molecules in the dataset included *ANK1*, *CD44*, *CD86*, *COL3A1*, *CRHR1*, *DIO2*, *FAS*, *FOS*, *FST*, *KDELR3*, *LBX1*, *MMP9*, *PPM1D*, *RUNX2*, and *TOP2A*. We measured the expression of Histone H3 (A, B for CA1 area and C for motor cortex), DNMT3A (A, C), and DNMT3B (A, D) in brain tissues of APP/PS1 and SAMP8 mice using immunohistochemistry, and the results showed that these DNA methyltransferases were up-regulated after treatment with alcohol extracts from *G. lucidum* ([Figure 7](#F7){ref-type="fig"}), indicating that *G. lucidum* can influence DNA methylation levels and that this may be an important signaling pathway influenced by *G. lucidum* in mediating its effects in delaying AD progression and/or aging.

![The networks of Ingenuity Canonical Pathways results of mRNA of APP/PS1 and SAMP8 mice brain tissues. Control and model group that received oral distilled water, AEG-treated group at a dosage of 100 mg/\[kg⋅d\] in AEG, and the extracts were dissolved in distilled water and were given by intragastric administration once daily for 24 weeks, alcohol (AEG) extracts from *G. lucidum* by gavage. **(A)** is the increased E2F3 signaling_upstream_regulator by AEG; **(B)** is increased RARA signaling_upstream_regulator by AEG and **(C)** is the Network of different expression mRNA using IPA pathway analysis.](fphar-10-00272-g006){#F6}

![The expression of Histone H3, DNMT3A and DNMT3B protein in the brain of alcohol extracts from *G. lucidum* treated APP/PS1 mice detected using IHC. Control and model group that received oral distilled water. Dosage of 50 mg/\[kg⋅d\] is AEGL, and 100 mg/\[kg⋅d\] is AEGH, and the extracts were dissolved in distilled water and were given by intragastric administration once daily for 24 weeks, alcohol (AEG) extracts from *G. lucidum* by gavage. **(A)** Brain tissue IHC detection; **(B--E)** Average optical density of brain tissue IHC detection. ^∗^*p* \< 0.05 and ^∗∗^*p* \< 0.01.](fphar-10-00272-g007){#F7}

Measurement of AD Related Markers
---------------------------------

Animals weighed approximately 32 g at the beginning and 38 g at the end of the experiment ([Figure 8A](#F8){ref-type="fig"}). Behavioral tests showed that alcohol extracts from *G. lucidum* (AEG-treated group) could significantly ameliorate learning and memory abilities, resulting in much improved times relative to the model group ([Figure 8B](#F8){ref-type="fig"}, *p* \< 0.05). Histopathological examination showed that treatment with alcohol extracts from *G. lucidum* could reduce the swelling of brain tissue, as Nissl's staining indicated that the CA1 area was larger, and there was an increased number of neurons ([Figure 8C](#F8){ref-type="fig"}, *p* \< 0.05 vs. model). Immunohistochemistry analysis indicated that alcohol extracts from *G. lucidum* could down-regulate the expression of the intracellular marker of AD, Aβ~1-42~, as there were fewer red fluorescent foci in brain tissues ([Figure 8C](#F8){ref-type="fig"}, *p* \< 0.05 vs. model).

![Effects of alcohol extracts from *Ganoderma lucidum* on APP/PS1 mice. **(A)** Body weight changes. **(B)** Escape corrected times analysis in the H type maze. **(C)** Nissl staining, expression of Aβ~1-42~ and Tau using immunofluorescence methods. AEG-treated group at a dosage of 100 mg/\[kg⋅d\] in AEG, and the extracts were dissolved in distilled water and were given by intragastric administration once daily for 24 weeks, alcohol (AEG) extracts from *G. lucidum* by gavage.](fphar-10-00272-g008){#F8}

Discussion
==========

Although analysis of methylation cannot reveal all the complex mechanisms underlying aging, it can reveal important information about the regulation of key genes related to aging and/or age-related diseases. Hence, exploration of methylation may be an effective approach to understanding the true causes of aging, through investigation of the molecular mechanisms involved in age-related methylation changes. Since the mechanisms underlying aging are not yet fully understood, such information is potentially of great clinical relevance and the delay of aging and/or prevention of age-related disease through determining optimal methylation states in aging, via measurement of whole genome hypomethylation and hypermethylation of specific genes, will be an important future research direction ([@B14]). In this context, we have explored natural small molecule compounds, and screened those with potential effects on the regulation of DNA methylation. *G. lucidum*, a folk remedy in Asia, exhibits marked effects in decreasing cell senescence and has antioxidant properties. In this study, we found that alcohol extracts from *G. lucidum* can improve [D]{.smallcaps}-galactose-induced learning and memory dysfunction in rats and ameliorate neuron apoptosis and brain atrophy. WGBS analysis showed that methylation levels of CpG sites in model group animals were 74.9%, which was lower than that of controls (77.5%), while in the AEG-treated group, levels recovered to 76.5%. Our experiments also demonstrated that *G. lucidum* alcohol extracts could improve learning and memory abilities, ameliorate neuron apoptosis and brain atrophy, and down-regulate the expression of the AD intracellular marker, Aβ~1-42~ in APP/PS1 AD model mice, while positive effects on DNA methylation were observed in SAMP8 and APP/PS1 mice.

Recent studies suggest that DNA methylation, a major epigenetic mechanism, is pivotal in the pathogenesis of age-related neurodegeneration and cognitive disorders ([@B15]). Moreover, epigenome alterations in adult somatic tissue may reflect age-associated deleterious events. Accumulation of genomic damage can lead to chromosomal instability and telomere shortening, reactive oxygen species-induced damage to mitochondrial functions and consequent reduced energy production, stem cell depletion, accumulation of damaged proteins via loss of proteostasis, processes leading to senescence and changes in intercellular communications and, finally, epigenome alterations. Many of these altered pathways are considered primary factors in age-related diseases, including cancer, neurodegenerative diseases, atherosclerosis, and inflammation. AD is associated with dysregulation of DNA methylation, histone modifications, and non-coding RNAs ([@B11]; [@B36]). Further, recent findings point to a role for 5hmC in the development of diseases, including AD, since global levels of 5mC and 5hmC are positively correlated with one another and with markers of AD, including amyloid beta, tau, and ubiquitin loads, potentially opening new pathways for AD treatment through correction of methylation and hydroxymethylation alterations ([@B10]). Hypermethylation targets include thromboxane A2 receptor (*TBXA2R*), sorbin, SH3 domain containing 3 (*SORBS3*), and spectrin beta 4 (*SPTBN4*), indicating that the cyclic AMP response element-binding protein (CREB) activation pathway and the axon initial segment may contribute to AD pathology ([@B24]). Akt2 ablation protects against cardiac aging through restoration of Foxo1-related autophagy and mitochondrial integrity ([@B23]). Moreover, DNA methylation is one possible epigenetic variation correlated with the occurrence of neural-tube defects, and AKT2 is a candidate gene associated with neural-tube defects ([@B20]). In this study, we used BSP to detect the methylation of CpG at the *AKT2* locus, and differences were detected between *G. lucidum*-treated and control mice ([Figure 5](#F5){ref-type="fig"}). Methylation of *AKT2* island 1 was 1.11% in AEG-APP/PS1, 3.33% in APP/PS1, and 2.22% in control mice (*p* \< 0.05, [Figure 5](#F5){ref-type="fig"}); while that of island 2 of *AKT2* was 2.31% for AEG-SAMP8, 4.31% for SAMP8, and 0.77% for control mice (*p* \< 0.05, [Figure 5](#F5){ref-type="fig"}).

p38α mitogen-activated protein kinase (MAPK) has been implicated in tau phosphorylation and inflammation; both of which are events associated with AD ([@B28]). The p38α MAPK pathway is activated by a dual phosphorylation at Thr180 and Tyr182 residues ([@B22]), and structure- and ligand-based drug design of novel p38-alpha MAPK inhibitors may represent a realistic strategy in the fight against AD. The methylation of *MAPK3* detected in this study was 3.20% in AEG-APP/PS1, 0.80% in AEG-SAMP8, 0.80% in APP/PS1, 1.26% in SAMP8, and 2.00% in control mice. These data demonstrate that alcohol extracts of *G. lucidum* can regulate DNA methylation, and we hypothesize that *AKT2* and *MAPK3* are potential methylation targets in AD; however, further studies are required.

The importance of methylation in aging is linked with another epigenetic modification, histone acetylation ([@B34]; [@B26]). A global reduction in gene expression, referred to as an epigenetic blockade, is observed in AD and may be regulated by post-translational modifications of histones ([@B13]). Histone H3 is strongly regulated by phosphorylation and the H3 sites, S57 and T58, exhibit lower levels of phosphorylation in the 5XFAD model than those detected in wild type controls, implicating these sites in the epigenetic blockade associated with neurodegeneration pathology ([@B1]). Epigenetic modifications, such as histone acetylation and deacetylation, are responsible for maintaining chromatin stability ([@B21]). Treatment modalities using various HDAC inhibitors, which can enhance synaptic plasticity, learning and memory, have emerged as potential new strategies for therapeutic intervention in neurodegenerative diseases, including AD, Huntington's disease, and Parkinson's disease ([@B15]). Analysis of polymorphisms of *DNMT3A* and *DNMT3B* support a major role for these loci in the pathogenesis of late-onset AD and these polymorphisms can be used as stratification markers to predict an individual's susceptibility to late-onset AD ([@B9]; [@B19]). The immunohistochemistry results reported here demonstrate that the Histone H3 DNA methyltransferases, DNMT3A and DNMT3B, were up-regulated in response to treatment with alcohol extracts from *G. lucidum* ([Figure 7](#F7){ref-type="fig"}), indicating that *G. lucidum* can influence these DNA methyltransferases to regulate the DNA methylation, and that this may be an important signaling pathway influenced by *G. lucidum* in delaying the progress of AD and/or aging. Overall, we conclude that *G. lucidum* alcohol extracts, including ganoderic acid and lucidone A, are the main active extracts that can contribute to delaying AD progression.
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